ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO836

Should We Discontinue Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Before Kidney Transplantation?

Session Information

Category: Transplantation

  • 2002 Transplantation: Clinical


  • Baek, Chung Hee, Asan Medical Center, Songpa-gu, Seoul, Korea (the Republic of)
  • Kim, Hyosang, Asan Medical Center, Songpa-gu, Seoul, Korea (the Republic of)
  • Park, Su-Kil, Asan Medical Center, Songpa-gu, Seoul, Korea (the Republic of)

Angiotensin converting enzyme inhibitors (ACEi) and Angiotensin receptor blockers (ARB) are usually recommended to stop before surgery to prevent post-operative acute kidney injury. However, it is uncertain that ACEi and ARB should be discontinued before kidney transplantation (KT). Therefore, we investigated the effect of pre-KT administration of ACEi and ARB on the outcomes of KT.


We reviewed patients who received living-donor KT in our tertiary center between 2018 and 2020. Among 923 patients, 291 patients continued ACEi/ARB within 3 days before KT (ACEi/ARB group), and 632 patients did not take ACEi/ARB within 3 days before KT (No ACEi/ARB group). Delayed graft function, hyperkalemia events, slope of creatinine after KT, rejection and graft survival were compared between two groups.


Baseline characteristics were not significantly different between two groups except medical history of hypertension (96.2% in ACEi/ARB group vs. 90.2% in no ACEi/ARB group, P=0.001) and number of re-transplantation (4.1% in ACEi/ARB group vs. 7.8% in no ACEi/ARB group, P=0.039). The numbers of ABO incompatible KT or HLA-sensitized KT, the degree of HLA mismatches and immunosuppressant were not different significantly between two groups. Delayed graft function occurred in 2 patients (0.7%) in ACEi/ARB group and 13 patients (2.1%) in no ACEi/ARB group (P=0.165). The event of hyperkalemia (K≥5.5 mEq/L) did not happen more frequently in ACEi/ARB group (21.3% vs. 22.9%, P=0.611, the day before KT; 11.3% vs. 10.1%, P=0.566, the day of surgery; 0.3% vs. 0.3%, P=1.000, the day after surgery). The slopes of creatinine from post-operative day 0 to day 7 were similar in two groups (-0.732±0.349 vs. -0.751±0.325, P=0.435). Rejection-free survival and graft survival were not significantly different between two groups (P=0.890 and 0.619 by Log-Rank test, respectively).


Use of ACEi/ARB before KT did not increase the incidence of delayed graft function, hyperkalemia and rejection. Also, renal function improvement after KT was not affected by the use of ACEi/ARB before KT. Therefore, ACEi/ARB might not give significant impact on the outcomes of KT. Further well-designed studies are necessary to confirm the effect of ACEi/ARB on KT.